Epstein Secrets

bserver), Sirna Therapeutics (NASDAQ: RNAI, acquired by Merck in 2006 for $1.1 billion), where he served as Chairman; Oriel Therapeutics (acquired by Novartis in 2010), where he served as Executive Chairman, and Pearl Therapeutics (acquired by AstraZeneca in 2012). Prior to joining Sprout, Jim was Chief Sci

CONFIDENTIAL HOUSE_OVERSIGHT_024083 X. CERTAIN TAX AND ERISA CONSIDERATIONS IN ACCORDANCE WITH U.S. TREASURY REGULATIONS GOVERNING PRACTICE BEFORE THE INTERNAL REVENUE SERVICE (CIRCULAR 230), LEGAL COUNSEL TO THE FUND HEREBY INFORMS INVESTORS THAT (A) THE INFORMATION BELOW (OR OTHERWISE CONTAINED IN THIS DOCUMENT) IS NOT IN

s, improving their effectiveness but shrinking their addressable markets. Drug companies will need to adapt their marketing strategies accordingly. Novartis CEO Joe Jimenez called out the explosion in DNA sequencing as a driver for R&D productivity "allowing new areas of discovery that have never been po

hat, although the Partnership intends to adopt positions it believes are in accord with current interpretations of the U.S. federal income tax laws, the Internal Revenue Service ("IRS") may not agree with the tax positions taken by the Partnership and that, if challenged by the IRS, the Partnership's tax positions might not

Owner Gets 3 Years For Concealing Income A California businessman will spend the next three years in federal prison for concealing his income from the Internal Revenue Service, the Department of Justice has announced. Read full article » INTELLECTUAL PROPERTY Texas Man Sentenced To 16 Months For Trade Secret Theft A Te

w to prepare for a future where technology and a new generation of talent and competitors will change the way attorneys work. Read full article » Novartis Taps Firms Ready To Pony Up On Diversity — Or Else Novartis AG on Wednesday said it has chosen nearly two dozen preferred law firms that have agree